Gosset Ownership
Private
Therapeutic Areas
Stage
Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Andira Pharmaceuticals General Information
Andira has completed pre-clinical safety studies for Silvanex™ Flex and is advancing toward clinical trials. Their lead products include Matrix3™ Shield for surgical site infection and a triple synergy antibiotic technology. As of May 2025, they are approximately one year away from entering Phase 1 clinical trials.
Contact Information
Drug Pipeline
Silvanex
Pre-clinicalKey Partnerships
US Capital Global, academic institutions and research hospitals (specific names not provided)
Andira Pharmaceuticals Funding
No funding data available
To view Andira Pharmaceuticals's complete valuation and funding history, request access »